A púrpura trombocitopênica trombótica (PTT) é uma doença rara e fatal que deve ser diagnosticada e tratada prontamente a fim de se obter melhor resposta terapêutica. Apresentamos um caso de PTT aguda grave tratada com plasmaférese e rituximabe. Ao diagnóstico, a paciente apresentava anemia hemolítica microangiopática, icterícia, febre, convulsões, seguidas por coma e choque hipovolêmico. Os exames laboratoriais iniciais mostravam DHL=2.860 IU/L, contagem de plaquetas de 37 x 10 9 /L, hemoglobina de 5,1 g/dL e no esfregaço de sangue periférico havia a presença de esquizócitos. Iniciado tratamento para PTT com pulsoterapia com metilprednisolona e plasmaféreses terapêuticas diárias com troca de uma volemia plasmática e substituição com plasma fresco congelado. Após cinco sessões de plasmaférese, houve piora no quadro neurológico, acompanhado por aumento importante de DHL, ALT, AST e a contagem de plaquetas era de 72 x 10 9 /L. Iniciamos o uso de rituximabe na dose padrão de 375mg/m 2 /semana/4 semanas e passamos a utilizar plasma pobre em crioprecipitado como reposição durante as plasmaféreses. Dois dias após a mudança na conduta terapêutica, houve importante melhora do quadro neurológico, estabilização da contagem de plaquetas e queda acentuada de DHL. Após 23 procedimentos de plasmaférese e quatro doses de rituximabe, a paciente apresentou remissão completa, mantida há 34 meses. A plasmaférese terapêutica com plasma pobre em crioprecipitado e o uso concomitante de rituximabe foi uma estratégia útil no tratamento deste caso de PTT aguda grave. Porém, ensaios clínicos prospectivos e randomizados são necessários para confirmar estes achados.
Background: Thrombotic thrombocytopenic purpura (TTP) is a rare and severe disease that must be diagnosed and treated promptly for a successful outcome. Case Report: In February 2005, a 44-year-old woman was admitted with severe microangiopathic hemolytic anaemia, jaundice, fever, seizures followed by coma and hypovolemic shock. She had joint pain 20 days before admission (anti-nuclear factor positive; 1/160) and had short-term episodes of bizarre behavior 1 week before admission. Her LDH was 2,860 IU/L; platelet count 37,000/mm3; hemoglobin 5.1 g/dl; blood smears contained schistocytes; AST 240 U/L; ALT 166 U/L; HIV and hepatitis seronegative, and CT normal at admission. TTP was diagnosed and pulse methylprednisolene initiated (1 g iv for 3 days) with single-volume daily plasma exchange using fresh frozen plasma. After two sessions, there was marginal neurological improvement, platelet count increased to 95,000/mm3 and LDH decreased to 2,199 IU/L. After six plasma exchanges, neurological status worsened, LDH increased sharply (7,139 IU/L) as did ALT (1,700 U/L), AST (3,000 U/L) and platelet count was 72,000/mm3. Rituximab (four, weekly 375 mg/m2 doses) and plasma exchange with cryosupernatant substitution fluid were initiated. The first plasma exchange was postponed until 24 hours after the first dose of rituximab and 48 hours after subsequent doses. Within two days, there was neurological improvement, stable platelet levels and decreased LDH. Complete remission was achieved after 23 plasma exchanges and four doses of Rituximab. Plasma exchange was tapered and the patient remained in sustained remission until now. There were episodes of hives related to plasma exchange, but no toxicity related to rituximab. Conclusion: Plasma exchange with cryosupernatant substitution fluid and rituximab had an important role in the successful treatment of this patient - a systematic clinical trial setting should be considered in order to confirm these findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.